Background {#Sec1}
==========

Sleep disturbance is a common symptom in patients with COPD \[[@CR1], [@CR2]\] and there are significant differences between the sleep disorders in patients with COPD and those encountered in the general population \[[@CR3]\]. Less rapid eye movement (REM) sleep and arousals during periods of desaturation are often noted in patients with COPD \[[@CR4]\]. Patients with COPD also become more hypoxemic during sleep than when awake and the hypoxemia during sleep is even greater than that encountered during exercise \[[@CR5]\]. Hypoventilation is the major cause of hypoxemia during REM sleep in patients with COPD and there may be additional contributions from ventilation-perfusion mismatches and reductions in functional residual capacity \[[@CR6]\].

Recently, Nunes et al. \[[@CR1]\] reported that 70 % of patients with COPD had poor sleep quality, and the quality of sleep was the major determinant of quality of life in those patients. In the study by Scharf et al. \[[@CR2]\] sleep quality was also associated with quality of life and sleep disturbance predicted poor survival in patients with COPD \[[@CR7]\]. However, the factors resulting in sleep disturbance are not well understood.

In patients with moderate to severe COPD, nocturnal desaturation did not correlate with sleep quality or quality of life \[[@CR8]\]. In another study, disturbed sleep was correlated with cough and dyspnea symptoms, but not with forced expiratory volume in the first second (FEV~1~) in patients with COPD \[[@CR7]\]. In addition, whether current pulmonary medications for COPD, including anticholinergics, theophylline, steroids, and beta2 agonists could improve or impair sleep quality is not well known \[[@CR9]--[@CR14]\]. This study was conducted, therefore, to identify the factors resulting in sleep disturbance in patients with COPD in Taiwan.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study was conducted in accordance with the amended Declaration of Helsinki. The study was approved by the Institutional Review Boards of all the hospitals involved.

A retrospective, observational, multicenter research study was performed across six participating hospitals, including four medical centers and two regional hospitals, three in northern Taiwan, one in center-western Taiwan, two in southwestern Taiwan. Between December 2011 and November 2013, patients over 40 years of age with COPD, who were followed in an outpatient pulmonary clinic, were enrolled. Patients with a COPD diagnosis, based on the Global Initiatives for Chronic Obstructive Lung Disease (GOLD) guidelines, were included \[[@CR15]\]. The GOLD guidelines are used worldwide in the diagnosis and management of COPD. COPD severity is staging by lung function only according to old GOLD guideline \[[@CR16]\]. According to the 2007 GOLD definition: Stage 1: FEV1 ≥ 80 % predicted; Stage: 2 FEV1 \< 80 % predicted and ≥ 50 % predicted; Stage 3: FEV1 \< 50 % predicted and ≥30 % predicted; and Stage 4: FEV1 \< 30 % predicted. In the GOLD guideline updated in 2011, COPD patients are classified into four groups by their symptoms and lung function \[[@CR15]\]. COPD symptoms were evaluated by mMRC or CAT as follows: less symptoms patient (A or C) : mMRC 0--1 or CAT \< 10; More symptoms patients (B or D): mMRC ≥ 2 or CAT ≥ 10. Low risk patients (A or B): FEV1% predicted ≥ 50 % or COPD exacerbation history 0--1; High risk patients (C or D): FEV1% predicted \< 50 % or COPD exacerbation history ≥ 2. The patients with COPD are categorized into A, B, C, and D, four groups.

All participants had pulmonary function tests within one year and at least one COPD Assessment Test (CAT) \[[@CR17]\], one Modified Medical Research Council (mMRC) dyspnea scale \[[@CR18]\], and one Pittsburgh Sleep Quality Index (PSQI) \[[@CR19]\]. Patients with a history of bronchial asthma or malignancy were excluded.

Data collection {#Sec4}
---------------

Medical records were retrospectively reviewed and analyzed for the following data: age, sex, body mass index (BMI), smoking status, COPD medications prescribed at outpatient clinics, clinical symptoms, presence of wheezing recorded in the medical charts, pulmonary function tests, and medical history of comorbidities. The COPD maintenance inhaler was defined as an inhaler continuously prescribed for 3 months.

Measures {#Sec5}
--------

The PSQI is a self-rating screening tool that measures quality of sleep. In addition to a total score, PSQI provides seven components of sleep including quality, latency, duration, efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and seven component scores are then summed to gain a global score \[[@CR19]\]. A PSQI global score \> 5 indicates poor sleep quality \[[@CR19]\]. The traditional Chinese version of PSQI was used to assess sleep quality in this study \[[@CR20]\]. The results of the PSQI questionnaire were retrospectively collected and analyzed. The CAT is a questionnaire for assessing the health status of COPD \[[@CR17]\]. The test has eight items including cough, phlegm, chest tightness, breathlessness, activities, confidence, sleep, and energy. Each item can be scored as a single scale (from 0 to 5) with total scores ranging from 0 to 40. Higher CAT scores indicate poorer health. The modified Medical Research Council (mMRC) scale include five statements for rating dyspnea from 0 to 4, and higher mMRC grades indicate more dyspnea \[[@CR18]\]. According to the GOLD guidelines, either a mMRC ≥ 2 or a CAT score ≥ 10 indicate more symptoms \[[@CR15]\].

Statistical analysis {#Sec6}
--------------------

Patient demographics, clinical characteristics, and medication use were summarized using descriptive statistics and data were expressed as mean ± standard deviation (SD). Comparisons between groups were made using the independent *t*-test, Chi-square test, one-way ANOVA, or Kruskal-Wallis one-way analysis of variance, where appropriate. Potential risk factors causing poor sleep quality in patients with COPD, including age, BMI, lung function, clinical symptoms, medications, medical history of comorbidities, and symptoms scores, were analyzed using univariate and multivariate analysis by applying a multiple logistic regression. All statistical analyses were performed using the using Statistical Analysis Software (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

A total of 377 stable patients with COPD and who attended the outpatient clinic and fulfilled the study criteria were analyzed. Table [1](#Tab1){ref-type="table"} shows the patients' characteristics, including age, sex, BMI, FEV~1~% predicted, FVC% predicted, GOLD group, comorbidities, and current COPD medication. Most patients were elderly and 98 % were male. According to the GOLD classification, most patients were classified into GOLD groups B and D. Among those classified, 53 % had poor sleep quality (PSQI \> 5).Table 1Demographic characteristics of the study population (*n* = 377)CharacteristicsMean ± SDAge, years73.0 ± 10.1Male sex, n (%)371 (98.4 %)BMI, (kg/m^2^)23.6 ± 3.0Smoking history Never smoker, n (%)22 (6.0 %) Ex-smoker, n (%)232 (63.0 %) Current smoker, n (%)114 (31 %)FEV~1~, L1.4 ± 0.5FEV~1~, predicted %59.8 ± 23.0Exacerbation in previous year, times0.6 ± 1.2Comorbidities Cardiovascular disease, n (%)157 (41.6 %) Ischemic heart disease, n (%)35 (9.3 %) Heart failure, n (%)15 (4.0 %) Hypertension, n (%)129 (34.2 %) Arrhythmia, n (%)19 (5.0 %) Depression, n (%)10 (2.7 %)Maintenance inhaler LABA, n (%)18 (4.8 %) LAMA, n (%)87 (23.1 %) LABA/LAMA, n (%)21 (5.6 %) LABA/ICS, n (%)72 (19.1 %) LAMA/ICS, n (%)3 (0.8 %) LABA/LAMA/ICS, n (%)90 (23.9 %) No maintenance inhaler, n (%)86 (22.8 %)GOLD classification Group A, n (%)60 (15.9 %) Group B, n (%)150 (39.8 %) Group C, n (%)34 (9.0 %) Group D, n (%)133 (35.3 %)PSQI score PSQI \>5, n (%)200 (53.1 %) PSQI≦5, n (%)177 (46.9 %)*Abbreviations*: *BMI* body mass index, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *FEV* ~*1*~ forced expiratory volume in the first second, *FVC* forced vital capacity, *ICS* inhaled corticosteroids, *LABA* long-acting beta agonists, *LAMA* long-acting muscarinic antagonist, *PSQI* Pittsburgh sleep quality index

Patients with COPD were divided by their pulmonary function tests according to the 2007 GOLD classification \[[@CR16]\]. Based on the 2007 GOLD classification system, the percentages of subjects with PSQI scores greater than 5 among the four groups was not significant (Table [2](#Tab2){ref-type="table"}).Table 2Measurements of COPD based on the 2007 GOLD classificationGOLD Stage 1GOLD Stage 2GOLD Stage 3GOLD Stage 4*P*-value*N* = 68*N* = 161*N* = 123*N* = 25MMRC, mean ± SD1.50 ± 0.761.78 ± 0.751.96 ± 0.952.33 ± 1.09\<0.001CAT, mean ± SD9.15 ± 6.919.53 ± 6.3511.07 ± 7.1116.83 ± 8.29\<0.001PSQI score, mean ± SD6.54 ± 3.576.43 ± 3.506.33 ± 3.666.44 ± 3.160.970PSQI \>5, n (%)36 (52.9)85 (52.8)64 (52.0)15 (60.0)0.910*Abbreviations*: *CAT* COPD assessment test, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *mMRC* modified Medical Research Council, *PSQI*, Pittsburgh Sleep Quality Index

The COPD patients were also classified using the 2011 GOLD classification system \[[@CR15]\], and the percentages of patients with PSQI \>5 between the GOLD groups A, B, C, and D were 43.3, 54.0, 38.2, and 60.2 %, respectively (*p* \< 0.05) (Table [3](#Tab3){ref-type="table"}).Table 3Measurements of COPD based on 2011 GOLD classificationGOLD group AGOLD group BGOLD group CGOLD group D*P*-value*N* = 60*N* = 150*N* = 34*N* = 133MMRC, mean ± SD0.87 ± 0.342.05 ± 0.580.72 ± 0.462.31 ± 0.81\<0.001CAT, mean ± SD4.52 ± 2.1411.09 ± 6.754.74 ± 2.6913.84 ± 7.08\<0.001PSQI score, Mean ± SD5.63 ± 2.926.67 ± 3.685.03 ± 3.296.85 ± 3.570.008PSQI \>5, n (%)26 (43.3 %)81 (54.0 %)13 (38.2 %)80 (60.2 %)0.046*Abbreviations*: *CAT* COPD assessment test, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *mMRC* modified Medical Research Council, *PSQI* Pittsburgh Sleep Quality Index

Table [4](#Tab4){ref-type="table"} demonstrated the specific components obtained from the PSQI. Among the seven components, sleep disturbance achieved the highest score compared with the other components. The most common sleep disturbances were "getting up to use the bathroom" (70.3 %), "wake up at night or early morning" (40.3 %) and "cough and snore loudly at night" (15.9 %). The percentage of the symptoms of sleep disturbance had no statistical difference between different stages of COPD according to the GOLD 2007 classification. (Table [5](#Tab5){ref-type="table"}) We divided the subjects by the 2011 GOLD classification, patients had high percentage of "wake up at night or early morning" and "get up to use the bathroom" on GOLD group B and group D (Table [6](#Tab6){ref-type="table"}).Table 4Sleep component scores based on the PSQI in patients with COPDComponentsMean ± SDSleep quality0.97 ± 0.75Sleep latency1.16 ± 1.09Sleep duration1.11 ± 0.94Sleep efficiency0.73 ± 1.04Sleep disturbance1.50 ± 0.59Use of sleeping medication0.47 ± 1.03Daytime dysfunction0.48 ± 0.66*Abbreviation*: *PSQI* Pittsburgh Sleep Quality IndexTable 5The distribution of sleep disturbances among patients with COPD based on 2007 GOLD classificationItems reporting ≥ 3 times per weekGOLD Stage 1GOLD Stage2GOLD Stage 3GOLD Stage 4*P*-valueN (%)N (%)N (%)N (%)Wake up at night or early morning29 (42.6 %)66 (41.0 %)43 (35.0 %)14 (56.0 %)0.240Get up to use the bathroom45 (66.2 %)118 (73.3 %)80 (65.0 %)22 (88.0 %)0.085Cannot breathe comfortably2 (2.9 %)11 (6.8 %)11 (8.9 %)4 (16.0 %)0.161Cough or snore loudly10 (14.7 %)23 (14.3 %)21 (17.1 %)6 (24.0 %)0.628Feel too cold0 (0.0 %)4 (2.5 %)2 (1.6 %)0 (0.0 %)0.508Feel too hot0 (0.0 %)4 (2.5 %)2 (1.6 %)1 (4.0 %)0.512Bad dreams9 (13.2 %)21 (13.0 %)13 (10.6 %)2 (8.0 %)0.829Pain3 (4.4 %)8 (5.0 %)7 (5.7 %)2 (8.0 %)0.910Table 6The distribution of sleep disturbances among patients with COPD based on 2011 GOLD classificationItems reporting ≥ 3 times per weekGOLD group AGOLD group BGOLD group CGOLD group D*P*-valueN (%)N (%)N (%)N (%)Wake up at night or early morning15 (25.0 %)70 (46.7 %)10 (29.4 %)57 (42.9 %)0.015Get up to use the bathroom37 (61.7 %)114 (76.0 %)19 (55.9 %)95 (71.4 %)0.047Cannot breathe comfortably0 (0.0 %)11 (7.3 %)2 (5.9 %)15 (11.3 %)0.050Cough or snore loudly8 (13.3 %)21 (14.0 %)4 (11.8 %)27 (20.3 %)0.383Feel too cold0 (0.0 %)4 (2.7 %)0 (0.0 %)2 (1.5 %)0.452Feel too hot0 (0.0 %)4 (2.7 %)0 (0.0 %)3 (2.3 %)0.487Bad dreams4 (6.7 %)26 (17.3 %)1 (2.9 %)14 (10.5 %)0.035Pain1 (1.7 %)9 (6.0 %)2 (5.9 %)8 (6.0 %)0.597

Table [7](#Tab7){ref-type="table"} shows the results of univariate analysis of variables associated with poor sleep quality (PSQI \> 5) in patients with COPD based on logistic regression. Inhaled corticosteroids and the presence of a wheeze showed positive correlations with poor sleep quality scores with odds ratios (ORs) of 1.66 and 1.51, respectively. The CAT and MMRC scores also correlated with PSQI scores with ORs of 1.09 (95 % confidence interval \[CI\], 1.05--1.13) and 1.30 (95 % CI, 1.02--1.66), respectively. Upon multivariate analysis, the CAT score remained an independent factor in poor sleep quality with an OR of 1.09 (95 % CI, 1.04--1.14; *p* \< 0.001).Table 7Variables associated with poor sleep quality among patients with COPDCharacteristicsParameter estimateStandard errorOdds ratio (95 % CI)*P*-valueUnivariate analysis Age0.0060.0101.01 (0.99,1.03)0.563 BMI0.0270.0261.03 (0.98,1.08)0.311 FEV~1~, predicted %−0.0030.0041.00 (0.99,1.01)0.555 Wheezing\*0.5090.2281.66 (1.06,2.60)0.026 Theophylline0.1340.5151.14 (0.42,3.14)0.794 Oral steroids−0.2810.2180.76 (0.49,1.16)0.197 Inhaled LABA−0.3630.4860.70 (0.27,1.80)0.455 Inhaled LAMA−0.3690.2450.69 (0.43,1.12)0.133 Inhaled ICS\*0.4120.2101.51 (1.00,2.28)0.049 Ischemic heart disease0.3120.3621.37 (0.67,2.77)0.389 Heart failure−0.5490.5370.58 (0.20,1.66)0.307 Hypertension0.4090.2201.50 (0.98,2.32)0.063 Arrhythmia0.4380.4871.55 (0.60,4.03)0.368 Depression1.2940.7973.65 (0.76,17.4)0.105 Anxiety−0.1240.8230.88 (0.18,4.43)0.880 CAT score\*0.0850.0171.09 (1.05,1.13)\<0.001 mMRC score\*0.2640.1251.30 (1.02,1.66)0.035*Abbreviations*: *BMI* body mass index, *FEV* ~*1*~ forced expiratory volume in the first second, *ICS* inhaled corticosteroids, *LABA* long-acting beta agonist, *LAMA* long-acting muscarinic antagonist, *CAT* COPD assessment test, *mMRC* modified Medical Research Council, *CI* confidence interval\**p* \< 0.05

To explore the factors contributing to poor sleep quality using the CAT score, the differences in CAT items between good and poor sleepers were further analyzed. Among all participants, 131 patients had all detailed specific items on COPD assessment tests recorded. Not surprisingly, "sleep problem" was one factor in poor sleepers. However, in addition, higher phlegm production was a significant factor in poor sleepers (Table [8](#Tab8){ref-type="table"}).Table 8Specific items on COPD Assessment Test between patients with COPD with poor sleep quality (PSQI \> 5) and those without poor sleep qualityWith poor sleep quality (*N* = 86)Without poor sleep quality (*N* = 45)*P*-valueCough2.0 ± 1.71.6 ± 1,30.123Phlegm\*2.4 ± 1.61.8 ± 1.50.030Chest tightness1.4 ± 1.41.1 ± 1.50.286Breathlessness2.4 ± 1.72.2 ± 1.90.558Activities1.0 ± 1.41.0 ± 1.60.805Confidence1.1 ± 1.51.1 ± 1.70.953Sleep\*2.1 ± 1.90.7 ± 1.4\<0.001Energy1.8 ± 1.61.4 ± 1.70.176CAT score\*14.4 ± 8.111.0 ± 7.90.022\**p* \< 0.05

Discussion {#Sec8}
==========

Our study demonstrated that 53 % of patients with COPD in our cohort had poor sleep quality (PSQI score \> 5). A high prevalence of poor sleep quality in patients with COPD has been reported in previous studies \[[@CR1], [@CR2], [@CR8]\]. In a recent real-world study, 78 % of patients with COPD reported night time disturbances as measured by the Jenkins Sleep Questionnaire \[[@CR21]\]. In a telephone study, Ohayon reported COPD subjects had higher insomnia symptoms than non-COPD subjects (48.1 versus 27.6 % respectively) \[[@CR22]\].

Our study also confirmed sleep disturbances, as well as cough and dyspnea, as major concerns in patients with COPD. Some researchers suggest that poor sleep quality might result in cognitive dysfunction, depression, anxiety, poor survival and poor quality of life \[[@CR7]\]. Determining which factors are associated with sleep disturbances in patients with COPD may improve their treatment strategy.

A high prevalence of sleep symptoms among patients with COPD was discovered approximately thirty years ago \[[@CR23]\] but poor sleep quality remained a forgotten dimension of COPD until recently \[[@CR24]\]. Few studies, however, have addressed factors such as medical history, pulmonary function tests, COPD medication, and questionnaires when analyzing sleep disturbances in COPD patients.

In this study, poor sleep quality was defined according to PSQI scores and included several symptoms. Interestingly, the most common symptoms that disturbed sleep in our COPD cohort were "getting up to use the bathroom" (69.9 %) and "wake up at night or early morning" (40.3 %) whereas "cough and snore loudly at night" or "bad dream" comprised the third and fourth complaints (15.9 and 11.9 %, respectively). Breathlessness, cough, sputum production, and wheezing were also among the most common symptoms in patients with COPD. In our study, we found the GOLD guideline updated in 2011, which was classified by their symptoms as well as lung function were related to sleep disturbance as shown in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [5](#Tab5){ref-type="table"}, and [6](#Tab6){ref-type="table"}. More symptoms patients (group B or group D; mMRC ≥ 2 or CAT ≥ 10) had a higher percentage of sleep disturbance including wake up at night or early morning, get up to use the bathroom, bad dream and cannot breathe comfortably.

In a nation-wide longitudinal population study, the overall prevalence of nocturnal voiding was 56 % at 50 years of age increasing to 74 % 10 years later \[[@CR25]\]. The average age of our cohort was 73 years of age with 69.9 % complaining of nocturnal voiding symptoms, similar to the results from the population study. An epidemiological study of nocturia by Yoshimura et al. suggested that, besides benign prostate hypertrophy, nocturia correlated with age, race, medical problems (such as hypertension, diabetes, and stroke) psychological problems, quality of life and mortality \[[@CR26]\]. Stephenson et al. reported that use of inhaled anticholinergic medications was associated with an increased risk of acute urinary retention in men with COPD, especially in those patients with benign prostate hyperplasia \[[@CR27]\]. However, another study concluded that tiotropium did not affect lower urinary tract function in patients with COPD \[[@CR28]\]. In our study, the use of inhaled long-acting muscarinic antagonists was not associated with poor sleep quality in the COPD patients. In patients with heart failure, nocturia is common and associated with sleep disturbance \[[@CR29]\]. Heart failure may be one of the factors contributing to sleep disturbance in the patients with COPD. Although the most common cause of sleep disturbance was getting up to use the bathroom, patients with poor sleep quality also had more complaints of "wake up at night or early morning", "cough or snore loudly", and "cannot breathe comfortably" compared with those patients without poor sleep quality. Thus, the current study offers physicians significant information regarding ways to discover and solve sleep problems in patients with COPD. In a national epidemiology survey in Taiwan \[[@CR30]\], males were predominated, especially in current and former smokers from 91 to 84 %. Our result had similar male predominant population which may due to our patients are mostly current or formal smokers.

Multivariate analysis showed that high CAT scores predicted poor sleep quality. These results implied that surveying the causes of sleep disturbance was important for patients with CAT scores \> 10. Mehta et. al also reported that COPD patients with high CAT scores had a higher frequency of insomnia than those with low CAT scores \[[@CR31]\]. A previous study reported an increased prevalence of night symptoms as the severity of airflow limitation increased \[[@CR32]\]. In contrast, another study found that FEV~1~ was not associated with disturbed sleep nor with health related quality of life \[[@CR7], [@CR33]\]. In our study, we found no relationship between pulmonary function tests and poor sleep quality. This result implies that poor sleep quality is not directly related to pulmonary function tests. However, other underlying diseases, medical comorbidities, and adverse effects of drug therapy may be associated factors.

The causes of sleep disturbance in patients with COPD are multifactorial, includes respiratory symptoms \[[@CR34]\], obstructive sleep apnea (OSA), psychiatric disorders, and medication-related insomnia \[[@CR9], [@CR35]\]. Sleep disturbances due to COPD medications is a common problem, and oral steroids, inhaled steroids, beta agonists, and theophylline have been implicated \[[@CR10], [@CR36]--[@CR38]\]. In our studies, the presence of wheeze, inhaled ICS, and significant phlegm production contributed to poor sleep quality. After multivariate analysis, however, no single medication caused poor sleep quality; only the CAT score predicted poor sleep quality in our COPD population. "Much phlegm" on the CAT questionnaire in our cohort was significant in poor sleepers. The CAT score is a simple questionnaire developed to assess and monitor the symptoms of COPD \[[@CR17]\]. We recommend the use of the CAT questionnaire rather than the MMRC to monitor symptoms of COPD because sleep disturbance is a major complaint in patients with COPD.

Our study had several limitations. We did not perform polysomnography to rule out sleep disorders such as OSA. Although OSA is prevalent in some selected COPD patients, the prevalence rate of OSA in patients with COPD was similar to the general population in the other reports \[[@CR24], [@CR39]\]. In addition, not all the factors which disturbed sleep (such as depression) were collected. The subjects included in our study may have had more medical comorbidities (and the percentage of GOLD B and D patients may have been higher) than those found in the general COPD population. Finally, the study was retrospective and the most data were collected in older men with COPD.

Conclusions {#Sec9}
===========

More than half of our patients with COPD experienced poor sleep quality. The most common sleep complaints included getting up for the bathroom, waking up at night or in the early morning, and coughing or snoring loudly. Symptoms including wheezing, phlegm, and the use of inhaled corticosteroid may also have contributed to poor sleep quality in these COPD patients.
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